Player FM 앱으로 오프라인으로 전환하세요!
02_05 Management of Metastatic Hormone Positive Breast Cancer
Manage episode 348943643 series 3335024
1. Endocrine Resistance: Definition and Mechanism
2. Role of AI with and without CDK4/6 inhibitors
3. Later line management of metastatic disease
4. Informative Censoring and the BOLERO-2 trial
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017
2. André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/
3. Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371
4. Piccart M et al. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456
5. Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653
6. Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6
7. Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217
8. Im SA et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/
9. Hortobagyi GN et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/
10. Finn RS et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/
11. Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/
12. Robertson JFR et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3
13. Mauri D et al. J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357
14. Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482
15. Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 에피소드
02_05 Management of Metastatic Hormone Positive Breast Cancer
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 348943643 series 3335024
1. Endocrine Resistance: Definition and Mechanism
2. Role of AI with and without CDK4/6 inhibitors
3. Later line management of metastatic disease
4. Informative Censoring and the BOLERO-2 trial
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017
2. André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/
3. Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371
4. Piccart M et al. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456
5. Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653
6. Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6
7. Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217
8. Im SA et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/
9. Hortobagyi GN et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/
10. Finn RS et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/
11. Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/
12. Robertson JFR et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3
13. Mauri D et al. J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357
14. Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482
15. Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 에피소드
Όλα τα επεισόδια
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.